Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02-Reference-Cited by-同舟云学术

Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02

Published:2024-09-11 Issue: Volume: Page:
ISSN:0741-238X
Container-title:Advances in Therapy
language:en
Short-container-title:Adv Ther

Author:

Oaknin Ana^ORCID,Lee Jung-Yun^ORCID,Makker Vicky^ORCID,Oh Do-Youn^ORCID,Banerjee Susana^ORCID,González-Martín Antonio^ORCID,Jung Kyung Hae^ORCID,Ługowska Iwona^ORCID,Manso Luis^ORCID,Manzano Aránzazu^ORCID,Melichar Bohuslav^ORCID,Siena Salvatore^ORCID,Stroyakovskiy Daniil^ORCID,Fielding Anitra,Puvvada Soham^ORCID,Smith Ann,Meric-Bernstam Funda^ORCID

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s12325-024-02975-x.pdf

Reference33 articles.

1. Ogitani Y, Aida T, Hagihara K, et al. DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1. Clin Cancer Res. 2016;22(20):5097–108.

2. U.S. Food and Drug Administration (FDA). ENHERTU (fam-trastuzumab deruxtecan-nxki): highlights of prescribing information. 2024. www.accessdata.fda.gov/drugsatfda_docs/label/2024/761139s028lbl.pdf. Accessed Jun 21, 2024.

3. Daiichi Sankyo. Press release. ENHERTU® approved in Japan as first HER2 directed therapy for patients with HER2 mutant metastatic non-small cell lung cancer. 2023. Available from: https://www.daiichisankyo.com/files/news/pressrelease/pdf/202308/20230823_E.pdf. Accessed Jun 21, 2024.

4. European Medicines Agency (EMA). ENHERTU: summary of product characteristics. 2024. Available from: https://www.ema.europa.eu/en/documents/product-information/enhertu-epar-product-information_en.pdf. Accessed Jun 21, 2024.

5. AstraZeneca. Enhertu approved in the US as first tumour-agnostic HER2-directed therapy for previously treated patients with metastatic HER2-positive solid tumours. 2024. Available from: https://www.astrazeneca.com/media-centre/press-releases/2024/enhertu-approved-in-the-us-as-first-tumour-agnostic-her2-directed-therapy-for-previously-treated-patients-with-metastatic-her2-positive-solid-tumours.html. Accessed Jun 21, 2024.